Fesoterodine: Difference between revisions
m (Protected "Fesoterodine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +)) |
||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
The [[antimuscarinic]] [[Fesoterodine]] is a drug developed by [[Schwarz Pharma AG]] to treat [[Overactive bladder syndrome]].<ref>{{cite web| url=http://www.medicalnewstoday.com/articles/41688.php| title=Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder - Pfizer To Acquire Exclusive Worldwide Rights| date=[[17 April]] [[2006]]|publisher=[[Medical News Today]]}}</ref> It was recommended for approval by the [[European Medicines Agency]] in February 2007, but is not yet available for use.{{Fact|date=November 2007}} | The [[antimuscarinic]] [[Fesoterodine]] is a drug developed by [[Schwarz Pharma AG]] to treat [[Overactive bladder syndrome]].<ref>{{cite web| url=http://www.medicalnewstoday.com/articles/41688.php| title=Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder - Pfizer To Acquire Exclusive Worldwide Rights| date=[[17 April]] [[2006]]|publisher=[[Medical News Today]]}}</ref> It was recommended for approval by the [[European Medicines Agency]] in February 2007, but is not yet available for use.{{Fact|date=November 2007}} | ||
| Line 7: | Line 7: | ||
{{reflist}} | {{reflist}} | ||
[[Category:Muscarinic antagonists]] | [[Category:Muscarinic antagonists]] | ||
Revision as of 02:40, 9 August 2012
|
WikiDoc Resources for Fesoterodine |
|
Articles |
|---|
|
Most recent articles on Fesoterodine Most cited articles on Fesoterodine |
|
Media |
|
Powerpoint slides on Fesoterodine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Fesoterodine at Clinical Trials.gov Clinical Trials on Fesoterodine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Fesoterodine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Fesoterodine Discussion groups on Fesoterodine Patient Handouts on Fesoterodine Directions to Hospitals Treating Fesoterodine Risk calculators and risk factors for Fesoterodine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Fesoterodine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
The antimuscarinic Fesoterodine is a drug developed by Schwarz Pharma AG to treat Overactive bladder syndrome.[1] It was recommended for approval by the European Medicines Agency in February 2007, but is not yet available for use.[citation needed]
References
- ↑ "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder - Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006. Check date values in:
|date=(help)